Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Genetix Biotherapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners across 2 distinct art units. This one-to-one ratio of examiners to art units suggests that each pending matter is being evaluated in a different specialized environment. For the practitioner, this means that the prosecution of the 2 pending office actions must be managed as two separate technical tracks.
TSUI, YUNG-SHENG M is the busiest examiner for this portfolio, with 1 pending office action. Given that there are 2 pending office actions and 2 distinct examiners, each examiner is responsible for exactly one action. This distribution requires the company to manage two separate prosecution strategies simultaneously within the pharmaceutical field. The presence of 2 distinct art units further confirms that the subject matter is being reviewed by different specialized groups. Practitioners must be careful to maintain consistency across the 2 distinct examiners while addressing the specific technical requirements of each art unit. This structure indicates a diversified biotechnology portfolio where each pending action faces a unique examination path.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TSUI, YUNG-SHENG M | 1 | 66.4% | +6.6% |
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576073 | METHODS | TSUI, YUNG-SHENG M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035683 | METHODS | WESTON, ALYSSA G | 62d |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576073 | METHODS | TSUI, YUNG-SHENG M | 1684 | §102§103 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18035683 | METHODS | WESTON, ALYSSA G | 1633 | §102 | Non-Final OA | 62d | Pending | May 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial